Advertisement

Viral Hepatitis in the Compromised Host

  • Jules L. Dienstag

Abstract

Four categories of viral hepatitis have been recognized: hepatitis A, hepatitis B, non-A, non-B hepatitis, and hepatitis B-associated delta hepatitis. Although all four have the potential to produce similar illnesses, clinical severity and outcome as well as the contribution of immunologic mechanisms to the clinical expression of infection and illness appear to differ among the various types. Observations of viral hepatitis in immunosuppressed persons have taught us important lessons about the biology of these viral agents, on the one hand, and about the approach to immunologically compromised patients with hepatitis, on the other. Unlike susceptibility of immunosuppressed persons to opportunistic infections, susceptibility to viral hepatitis per se is not increased in the immunosuppressed; however, because patients with immunologic derangements are very likely to require transfusions of blood products, the frequency of viral hepatitis in this group of patients is increased. In addition, severity of acute illness, likelihood of chronic infection, infectivity, and the early and late consequences of chronic infection differ distinctly between immunocompetent and immunosuppressed hosts.

Keywords

Down Syndrome Viral Hepatitis Renal Transplant Recipient Chronic Active Hepatitis Chronic Persistent Hepatitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Szmuness W, Purcell RH, Dienstag JL, et al: Antibody to hepatitis A antigen in institutionalized mentally retarded patients. JAMA 237: 1702–1705, 1977.PubMedCrossRefGoogle Scholar
  2. 2.
    Szmuness W, Dienstag JL, Purcell RH, et al: Hepatitis type A and hemodialysis: A seroepidemiologic study in 15 U.S. centers. Ann Intern Med 87: 8–12, 1977.PubMedGoogle Scholar
  3. 3.
    Rizzetto M: The delta agent. Hepatology 3: 729–737, 1983.PubMedCrossRefGoogle Scholar
  4. 4.
    Popper H, Thung SN, Gerber MA, et al: Histologic studies of severe delta agent infection in Venezuelan Indians. Hepatology 3: 906–912, 1983.PubMedCrossRefGoogle Scholar
  5. 5.
    Friedman LS, Dienstag JL: The disease and its pathogenesis. In Gerety RJ (ed): Hepatitis A, Academic, Orlando, Florida, 1984, pp. 55–79.Google Scholar
  6. 6.
    Dienstag JL, Bhan AK, Klingenstein RJ, et al: Immunopathogenesis of liver disease associated with hepatitis B. In Szmuness W, Alter HI, Maynard JE (eds): Viral Hepati-tis-1981 International Symposium, Franklin Institute, Philadelphia, 1982, pp. 221–236.Google Scholar
  7. 7.
    Dienstag IL: Immunologic mechanisms in chronic viral hepatitis. In Vyas GN, Dienstag JL, Hoofnagle JH (eds): Viral Hepatitis and Liver Disease. Grune Stratton, Orlando, Florida, 1984, pp. 135–166.Google Scholar
  8. 8.
    Blumberg BS, Sutnick AI, London WT: Australia antigen as a hepatitis virus: Variation in host response. AmJMed 48: 18, 1970.Google Scholar
  9. 9.
    Blumberg BS, Gerstley BJS, Hungerford DA, et al: A serum antigen (Australia antigen) in Down’s syndrome, leukemia and hepatitis. Ann Intern Med 66: 924–931, 1967.PubMedGoogle Scholar
  10. 10.
    Blumberg BS, Sutnick AI, London WT: Hepatitis and leukemia: Their relation to Australia antigen. Bull NY Acad Med 44: 1566–1586, 1968.Google Scholar
  11. 11.
    Szmuness W, Harley EJ, Ikram H, et al: Sociodemographic aspects of the epidemiology of hepatitis B. In Vyas GN, Cohen SN, Schmid R (eds): Viral Hepatitis. Franklin Institute, Philadelphia, 1978, pp. 297–320.Google Scholar
  12. 12.
    Markenson JA, Gerety RJ, Hoofnagle JH, et al: Effects of cyclophosphamide on hepatitis B virus infection and challenge in chimpanzees. J Infect Dis 131: 79–87, 1975.PubMedCrossRefGoogle Scholar
  13. 13.
    Galbraith RM, Eddleston ALWF, Williams R, et al: Fulminant hepatic failure in leukemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet 2: 528–530, 1975.PubMedCrossRefGoogle Scholar
  14. 14.
    Sagnelli E, Manzillo G, Maio G, et al: Serum levels of hepatitis B surface and core antigens during immunosuppressive treatment of HBsAg-positive chronic active hepatitis. Lancet 2: 395–397, 1980.PubMedCrossRefGoogle Scholar
  15. 15.
    Scullard GH, Smith CI, Merigan TC, et al: Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B. Gastroenterology 81: 987–991, 1981.PubMedGoogle Scholar
  16. 16.
    Villa E, Theodossi A, Portman B, et al: Reactivation of hepatitis B virus infection in two patients: Immunofluorescence studies of liver tissue, Gastroenterology 80: 1048–1053, 1981.PubMedGoogle Scholar
  17. 17.
    Reed WD, Eddleston ALWF, Cullens H, et al: Infusion of hepatitis B antibody in antigen-positive active chronic hepatitis. Lancet 2: 1347–1451, 1975.Google Scholar
  18. 18.
    Kohler PF, Trembath J, Merrill DA, et al: Immunotherapy with antibody, lymphocytes and transfer factor in chronic hepatitis B. Clin lmmunollmmunopathol 2: 465–471, 1974.CrossRefGoogle Scholar
  19. 19.
    Thomas HC, Chadwick RG, Jain S, et al: Levamisole therapy for HBs antigen positive chronic liver disease Gastroenterology 73:A52, 1977 (abst.).Google Scholar
  20. 20.
    Jain, S, Thomas HC, Sherlock S: Transfer factor in the attempted treatment of patients with HBsAg-positive chronic liver disease. Clin Exp Immunol 30: 10–15, 1977.PubMedGoogle Scholar
  21. 21.
    Good RA, Page AR: Fatal complications of virus hepatitis in two patients with agammaglobulinemia. Am J Med 29: 804–810, 1960.PubMedCrossRefGoogle Scholar
  22. 22.
    Mondelli M, Mieli Vergani G, Alberti A, et al: Specificity of T lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection: Evidence that T cells are directed against HBV core antigen expressed on hepatocytes. J Immunol 129: 2773–2778, 1982.PubMedGoogle Scholar
  23. 23.
    Naumov NV, Mondelli M, Alexander GJM, et al: Relationship between expression of hepatitis B virus antigens inisolated hepatocytes and autologous lymphocyte cytotoxicity in patients with chronic hepatitis B virus infection. Hepatology 4: 63–68, 1984.PubMedCrossRefGoogle Scholar
  24. 24.
    Ceuppens JL, Stevens E, Fevery J, et al: Complete recovery from hepatitis B and associated hemolysis in a patient with underlying T-cell deficiency. Gastroenterology 86: 937–940, 1984.PubMedGoogle Scholar
  25. 25.
    Romet-Lemonne JL, McLane MF, Elfassi E, et al: Hepatitis B virus infection in cultured human lymphoblastoid cells. Science 221: 667–669, 1983.PubMedCrossRefGoogle Scholar
  26. 26.
    Dienstag JL: Non-A, non-B hepatitis. I. Recognition, epidemiology, and clinical features. Gastroenterology 85: 439–462, 1983.PubMedGoogle Scholar
  27. 27.
    Dienstag JL: Non-A, non-B hepatitis. II. Experimental transmission, putative virus agents and markers, and prevention. Gastroenterology 85: 743–768, 1983.PubMedGoogle Scholar
  28. 28.
    Blumberg BS, Alter HJ, Visnich S: A “new” antigen in leukemia sera. JAMA 191: 541–546, 1965.PubMedCrossRefGoogle Scholar
  29. 29.
    Goldblum SE, Reed WP: Host defenses and immunologic alterations associated with chronic hemodialysis. Ann Intern Med 93: 597–613, 1980.PubMedGoogle Scholar
  30. 30.
    Agarwal SS, Blumberg BS, Gerstley BS, et al: DNA polymerase activity as an index of lymphocyte stimulation: Studies in Down’s syndrome. J Clin Invest 49: 161–169, 1970.PubMedCrossRefGoogle Scholar
  31. 31.
    Boughton CR, Hawkes RA, Schroeter DR, et al: The epidemiology of hepatitis B in a residential institution for the mentally retarded. Aust NZ J Med 6: 521–529, 1976.CrossRefGoogle Scholar
  32. 32.
    Hawkes RA, Boughton CR, Schroeter DR, et al: Hepatitis B infection in institutionalized Down’s syndrome inmates: A longitudinal study with five hepatitis B virus markers. Clin Exp Immunol 40: 478–486, 1980.PubMedGoogle Scholar
  33. 33.
    Madden DL, Dietzman DE, Matthew EB, et al: Epidemiology of hepatitis B virus in an institution for mentally retarded persons. Am J Ment Defic 80: 369–375, 1976.PubMedGoogle Scholar
  34. 34.
    Chaudhary RK, Perry E, Cleary TE: Prevalence of hepatitis B infection among residents of an institution for the mentally retarded. Am J Epidemiol 105: 123–126, 1977.PubMedGoogle Scholar
  35. 35.
    Szmuness W, Pick R, Prince AM: The serum hepatitis virus specific antigen (SH): A preliminary report of epidemiologic studies in an institution for the mentally retarded. Am J Epidemiol 92: 51–61, 1970.PubMedGoogle Scholar
  36. 36.
    Hollingsworth DR, Hollingsworth JW, Roeckel I, et al: Immunologic reactions and Australia antigenemia in Down’s syndrome. J Chron Dis 27: 483–490, 1974.PubMedCrossRefGoogle Scholar
  37. 37.
    Szmuness W, Neurath AR, Stevens CE, et al: Prevalence of hepatitis B “e” antigen and its antibody in various HBsAg carrier populations. Am J Epidemiol 113: 113–121, 1981.PubMedGoogle Scholar
  38. 38.
    Garibaldi RA, Forrest JN, Bryan JA, et al: Hemodialysisassociated hepatitis. JAMA 225: 384–389, 1973.PubMedCrossRefGoogle Scholar
  39. 39.
    Snydman DR, Bryan JA, Hanson B: Hemodialysis-associated hepatitis in the United States-1972. J Infect Dis 132: 109–113, 1975.PubMedCrossRefGoogle Scholar
  40. 40.
    Szmuness W, Prince AM, Grady GF, et al: Hepatitis B infection: A point-prevalence study in 15 US hemodialysis centers. JAMA 227: 901–906, 1974.PubMedCrossRefGoogle Scholar
  41. 41.
    Centers for Disease Control: Hepatitis-Control measures for hepatitis B in dialysis centers. Viral hepatitis investigations and control series. U.S. Department of Health, Education and Welfare, Phoenix, November 1977, pp. 1–9.Google Scholar
  42. 42.
    Szmuness W: Large-scale efficacy trials of hepatitis B vaccines in the USA: Baseline data and protocols: J Med Virol 4: 327–340, 1979.PubMedCrossRefGoogle Scholar
  43. 43.
    Sengar DPS, Rashid A, McLeish WA, et al: Hepatitis B surface antigen (HBsAg) infection in a hemodialysis unit. II. Factors affecting host immune response to HBsAg. Can Med Assoc J 113: 945–948, 1975.PubMedGoogle Scholar
  44. 44.
    London WT, Drew JS, Lustbader ED, et al: Host responses to hepatitis B infection in patients in a chronic hemodialysis unit. Kidney Int 12: 51–58, 1977.PubMedCrossRefGoogle Scholar
  45. 45.
    Snydman DS, Bregman D, Bryan JA: Hemodialysis-associated hepatitis in the United States, 1974. J Infect Dis 135: 687–691, 1977.CrossRefGoogle Scholar
  46. 46.
    Ribot S, Rothstein M, Goldblat M, et al: Duration of hepatitis B surface antigenemia (HBsAg) in hemodialysis patients. Arch Intern Med 139: 178–180. 1979.PubMedCrossRefGoogle Scholar
  47. 47.
    Gahl GM, Hess G, Arnold W, et al: Hepatitis B virus markers in 97 long-term hemodialysis patients. Nephron 24: 58–63, 1979.PubMedCrossRefGoogle Scholar
  48. 48.
    Beorchia S, Trepo C, Betuel H, et al: Interest of HBeAg in the study of immunogenetic factors influencing HBV infection in hemodialysed and kidney transplanted patients. In Touraine JL, Traeger J, Betuel H, et al (eds): Transplantation and Clinical Immunology. Vol 10. Excerpta Medica, Amsterdam, 1979, pp. 44–49.Google Scholar
  49. 49.
    Snydman DR, Bryan JA, Macon EJ, et al: Hemodialysisassociated hepatitis: Report of an epidemic with further evidence on mechanisms of transmission. Am J Epidemiol 104: 563–570, 1976.PubMedGoogle Scholar
  50. 50.
    Garibaldi RA, Hatch FE, Bisno AL, et al: Nonparenteral serum hepatitis: Report of an outbreak. JAMA 220: 963–966, 1972.PubMedCrossRefGoogle Scholar
  51. 51.
    Coughlin GP, Van Deth AG, Disney APS, et al: Liver disease and the e antigen in HBsAg carriers with chronic renal failure. Gut 21: 118–122, 1980.PubMedCrossRefGoogle Scholar
  52. 52.
    Degott C, Degos F, Jungers P, et al: Relationship between liver histopathological changes and HBsAg in 111 patients treated by long-term hemodialysis. Liver 3: 377–384, 1983.PubMedGoogle Scholar
  53. 53.
    Jungers P, Naret C, Degott C, et al: Histological and immunological survey of chronic active hepatitis in 650 hemodialyzed patients. In Touraine JL, Traeger J, Betuel H, et al (eds): Transplantation and Clinical Immunology. Vol. 10. Excerpta Medica, 1979, pp. 38–43.Google Scholar
  54. 54.
    Galbraith RM, Dienstag JL, Purcell RH, et al: Non-A non-B hepatitis associated with chronic liver disease in a hemodialysis unit. Lancet 1: 951–953, 1979.PubMedCrossRefGoogle Scholar
  55. 55.
    Galbraith RM, Portmann B, Eddleston ALWF, et al: Chronic liver disease developing after outbreak of HBsAg-negative hepatitis in haemodialysis unit. Lancet 2: 886–890, 1975.PubMedCrossRefGoogle Scholar
  56. 56.
    Marmion BP, Burrell CJ, Tonkin RW, et al: Dialysis-associated hepatitis in Edinburgh, 1969–1978. Rev Infect Dis 4: 619–637, 1982.PubMedCrossRefGoogle Scholar
  57. 57.
    Coursaget P, Maupas P, Dubois F, et al: Hepatites non-A, non-B chez six malades hemodialyses. Nouv Presse Med 7: 3515–3519, 1978.Google Scholar
  58. 58.
    Mery JP, Simon N, Courouce AM: Hepatite non-A, non-B chez les hemodialyses chroniques: 5 observations. Nouv Presse Med 8: 3973, 1979.Google Scholar
  59. 59.
    Koretz RL, Stone O, Brezina M, et al: Chronic hepatitis in the dialysis unit: Etiologic considerations. Gastroenterology 78:1198, 1980 (abst).Google Scholar
  60. 60.
    Dienstag JL, Stevens CE, Szmuness W: The epidemiology of non-A, non-B hepatitis: Emerging patterns. In Gerety JR (ed): Non-A, non-B Hepatitis. Academic, New York, 1981, pp. 119–137.Google Scholar
  61. 61.
    Simon N, Mery JP, Trepo C, et al: A non-A, non-B hepatitis epidemic in a HB antigen-free hemodialysis unit: Demonstration of serological markers of non-A, non-B virus, Proc Eur Dial Transplant Assoc 17: 173–178, 1980.PubMedGoogle Scholar
  62. 62.
    Avram MM, Feinfeld DA, Gan AC: Non-A, non-B hepatitis: A new syndrome in uraemic patients. Proc Eur Dial Transplant Assoc 16: 141–147, 1979.PubMedGoogle Scholar
  63. 63.
    Wolf JL, Perkins HA, Schreeder MT, et al: The transplanted kidney as a source of hepatitis B infection. Ann Intern Med 91: 412–413, 1979.PubMedGoogle Scholar
  64. 64.
    Lutwick LI, SyWassink JM, Corry RJ, et al: The renal transplant as a source of hepatitis B virus (HBV). Clin Res 29:258A, 1981 (abst.).Google Scholar
  65. 65.
    Degos F, Degott C, Bedrossian J, et al: Is renal transplantation involved in post-transplantation liver disease? A prospective study. Transplantation 29: 100–102, 1980.PubMedCrossRefGoogle Scholar
  66. 66.
    Toussaint C, Thiry L, Kinnaert P, et al: Prognostic significance of hepatitis B antigenemia in kidney transplantation. Nephron 17: 335–342, 1976.PubMedCrossRefGoogle Scholar
  67. 67.
    Luby JP, Burnett W, Hull AR, et al: Relationship between cytomegalovirus and hepatic function abnormalities in the period after renal transplant. J Infect Dis 129: 511–518, 1974.PubMedCrossRefGoogle Scholar
  68. 68.
    Kaiser L, Kelly TJ, Patterson MJ, et al: Hepatitis B surface antigen in urine of renal transplant recipients. Ann Intern Med 94: 783–784, 1981.PubMedGoogle Scholar
  69. 69.
    Mayor GH, Kelly TJ, Hourani MR, et al: Intermittent hepatitis B surface antigenuria in a renal transplant recipient. Am J Med 68: 305–307, 1980.PubMedCrossRefGoogle Scholar
  70. 70.
    Nagington J, Cossait YE, Cohen BJ: Reactivation of hepatitis B after transplantation operations. Lancet 1: 558–560, 1977.PubMedCrossRefGoogle Scholar
  71. 71.
    Dusheiko G, Song E, Bowyer S, et al: Natural history of hepatitis B virus infection in renal transplant recipients—A fifteen-year follow-up. Hepatology 3: 330–336, 1983.PubMedCrossRefGoogle Scholar
  72. 72.
    London WT, Drew JS, Blumberg BS, et al: Association of graft survival with host response to hepatitis B infection in patients with kidney transplants. N Engl J Med 296: 24 1244, 1977.Google Scholar
  73. 73.
    London WT, Jarvinen H, Jasko L, et al: Hepatitis B virus infection in kidney transplant recipients. In Bianchi L, Gerok W, Sickinger K, et al (eds): Virus and the Liver. MTP Press, Lancaster, 1980, pp. 267–276.Google Scholar
  74. 74.
    Jarvinen H, Shofer FS, Burke JF, et al: Antibody to hepatitis B surface antigen and kidney graft survival. Transplant Proc 15: 1094–1098, 1983.Google Scholar
  75. 75.
    Toussaint C, Cappel R, Vereerstraeten P, et al: Graft survival and response to hepatitis-B virus in kidney recipients. Transplant Proc 11: 89–92, 1979.PubMedGoogle Scholar
  76. 76.
    Pirson Y, Alexandre GPJ, van Ypersele de Strihou C: Longterm effect of HBs antigenemia on patient survival after renal transplantation. N Engl J Med 296: 194–196, 1977.PubMedCrossRefGoogle Scholar
  77. 77.
    Hillis WD, Hillis A, Walker WG: Hepatitis B surface antigenemia in renal transplant recipients: Increased mortality risk. JAMA 242: 329–332, 1979.PubMedCrossRefGoogle Scholar
  78. 78.
    Chatterjee SN, Payne JE, Bischell MD, et al: Successful renal transplantation in patients positive for hepatitis B antigen. N Engl J Med 291: 62–65, 1974.PubMedCrossRefGoogle Scholar
  79. 79.
    Berne TV, Fitzgibbons TJ, Silberman H: The effect of hepatitis B antigenemia on long-term success and hepatic disease in renal transplantation. Transplantation 24: 412–415, 1977.PubMedCrossRefGoogle Scholar
  80. 80.
    Fine RN, Malekzadeh MH, Pennisi Ai, et al: HBs antigenemia in renal allograft recipients. Ann Surg 185: 411–416, 1977.PubMedCrossRefGoogle Scholar
  81. 81.
    Ponticelli C, De Vecchi A, Cantaluppi A, et al: Hepatitis and renal transplants. (Letter.) N Engl J Med 296: 1170, 1977.Google Scholar
  82. 82.
    Rashid A, Sengar D, Couture R, et al: Hepatitis and renal transplants. (Letter.) N Engl J Med 296: 1170–1171, 1977.Google Scholar
  83. 83.
    Hillis WD, Hillis A, Bias WB. et al: Association of hepatitis B surface antigenemia with HLA locus B specificities. N Engl J Med 296: 1310–1314, 1977.PubMedCrossRefGoogle Scholar
  84. 84.
    Opelz G, Terasaki PI: Graft survival rates and HLA antigen frequencies in renal cadaver transplant recipients with hepatitis B antigenemia. Transplantation 25: 159–161, 1978.PubMedCrossRefGoogle Scholar
  85. 85.
    Parfrey PS, Forbes RDC, Hutchinson TA, et al: The clinical and pathological course of hepatitis B liver disease in renal transplant recipients. Transplantation 37: 461–466, 1984.PubMedCrossRefGoogle Scholar
  86. 86.
    Schroter GPJ, Weill R III, Penn I, et al: Hepatocellular carcinoma associated with chronic hepatitis B virus infection after kidney transplantation. (Letter.) Lancet 2: 381–382, 1982.PubMedCrossRefGoogle Scholar
  87. 87.
    Anuras S, Piros J, Bonney WW, et al: Liver disease in renal transplant recipients. Arch Intern Med 137: 42–48, 1977.PubMedCrossRefGoogle Scholar
  88. 88.
    Strom TB: Hepatitis B, transfusions, and renal transplantation—five years later. (Editorial.) N Engl J Med 307: 1141–1142, 1982.PubMedCrossRefGoogle Scholar
  89. 89.
    Berne TV, Chatterjee SN, Craig JR, et al: Hepatic dysfunction in recipients of renal allografts. Surg Gynecol Obstet 141: 171–175, 1975.PubMedGoogle Scholar
  90. 90.
    Mozes MF, Ascher NL, Balfour HHJ, et al: Jaundice after ’ renal allotransplantation. Ann Surg 188: 783–790, 1978.PubMedCrossRefGoogle Scholar
  91. 91.
    Ware AJ, Luby JP, Hollinger B, et al: Etiology of liver disease in renal-transplant patients. Ann Intern Med 91: 364–371, 1979.PubMedGoogle Scholar
  92. 92.
    Alvarez V, Plaza JJ, Carreno V, et al: Viral infections and liver damage in renal transplant patients. Gastroenterology 79:1001, 1980 (abst.).Google Scholar
  93. 93.
    Fennell RS 111, Andres JM, Pfaff WW, et al: Liver dysfunction in children and adolescents during hemodialysis and after renal transplantation. Pediatrics 67: 855–861, 1981.PubMedGoogle Scholar
  94. 94.
    LaQuaglia MP, Tolkoff-Rubin NE, Dienstag JL, et al: Impact of hepatitis on renal transplantation. Transplantation 32: 504–507, 1981.PubMedCrossRefGoogle Scholar
  95. 95.
    Alter HJ, Hoofnagle JH: Non-A, non-B: Observations on the first decade. In Vyas GN, Dienstag JL, Hoofnagle JH (eds): Viral Hepatitis and Liver Disease. Grune Stratton, Orlando, 1984, pp. 345–354.Google Scholar
  96. 96.
    Wyke RI, Williams R: Clinical aspects of non-A, non-B hepatitis infection. J Virol Methods 2: 17–29, 1980.PubMedCrossRefGoogle Scholar
  97. 97.
    Sutnick AI, London WT, Blumberg BS, et al: Australia antigen (a hepatitis associated antigen) in leukemia. J Natl Cancer Inst 44: 1241–1249, 1970.PubMedGoogle Scholar
  98. 98.
    Sutnick AI, Levine PH, London WT, et al: Frequency of Australia antigen in patients with leukemia in different countries. Lancet 1: 1200–1202, 1971.PubMedCrossRefGoogle Scholar
  99. 99.
    Grange MJ, Erlinger S, Teilletd F, et al: A possible relationship to treatment between hepatitis-associated antigen and chronic persistent hepatitis in Hodgkin’s disease. Gut 14: 433–437, 1973.PubMedCrossRefGoogle Scholar
  100. 100.
    Wands JR, Chura CM, Roll FJ, et al: Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 68: 105–112, 1975.PubMedGoogle Scholar
  101. 101.
    Wands JR, Walker JA, Davis Ti’, et al: Hepatitis B in an oncology unit. N Engl J Med 291: 1371–1375, 1974.PubMedCrossRefGoogle Scholar
  102. 102.
    Schulman AN, Fagen ND, Brezina M, et al: HBe-antigen in the course and prognosis of hepatitis B infection: A prospective study. Gastroenterology 78: 253–258, 1980.PubMedGoogle Scholar
  103. 103.
    Trinchet IC, Beaugrand M, Hecht Y, et al: Hépatite fulminante à virus B survenue au cours d’un traitement immunodepresseur. Gastroenterol Clin Biol 4: 59–62, 1980.PubMedGoogle Scholar
  104. 104.
    Hoofnagle JH, Dusheiko GM, Schafer DF, et al: Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 96: 447–449, 1982.PubMedGoogle Scholar
  105. 105.
    Vergani D, Locasciulli A, Masera G, et al: Histological evidence of hepatitis-B-virus infection with negative serology in children with acute leukemia who develop chronic liver disease. Lancet 1: 361–364, 1982.PubMedCrossRefGoogle Scholar
  106. 106.
    Wade JC, Gaffey M, Wiernik PH, et al: Hepatitis in patients with acute nonlymphocytic leukemia, Am J Med 75: 413–422, 1983.PubMedCrossRefGoogle Scholar
  107. 107.
    Locasciulli A, Santamaria M, Masera G, et al: Hepatitis B virus markers in children with acute leukemia: The effect of chemotherapy. J Med Virol 15: 29–33, 1985.PubMedCrossRefGoogle Scholar
  108. 108.
    Cowan DH, Kouroupis GM, Leers W-D: Occurrence of hepatitis and hepatitis B surface antigen in adult patients with acute leukemia. Can Med Assoc J 112: 693–697, 1975.PubMedGoogle Scholar
  109. 109.
    Sauerbruch T, Frosner G, Theml H, et al: Hepatitis B-virusmarker and rotelnantikorper bei patienten mit hodgkin-, non-hodgkin-lymphomen and allgemein internistischen erkrankungen. Blut 40: 259–266, 1980.PubMedCrossRefGoogle Scholar
  110. 110.
    Tabor E, Gerety RI, Mott M, et al: Prevalence of hepatitis B in a high risk setting: A serlogic study of patients and staff in a pediatric oncology unit. Pediatrics 61: 711–715, 1978.PubMedGoogle Scholar
  111. 111.
    Weitberg AB, Weitzman SA, Watkins E, et al: Immunogenicity of hepatitis B vaccine in oncology patients receiving chemotherapy. J Clin Oncol 3: 718–722, 1985.PubMedGoogle Scholar
  112. 112.
    Schulman AN, Fagen ND, Ling CM, et al: Repeated type B hepatitis infections: Ten case studied prospectively. Gastroenterology 72:1182, 1977 (abst).Google Scholar
  113. 113.
    Lightdale CJ, Ikram H, Pinsky C: Primary hepatocellular carcinoma with hepatitis B antigenemia: Effects of chemotherapy. Cancer 46: 1117–1122, 1980.PubMedCrossRefGoogle Scholar
  114. 114.
    Steinberg SC, Alter Hi, Leventhal BG: The risk of hepatitis transmission to family contacts of leukemia patients. J Pediatr 87: 753–757, 1975.PubMedCrossRefGoogle Scholar
  115. 115.
    Wands JR: Subacute and chronic active hepatitis after withdrawal of chemotherapy. (Letter.) Lancet 2: 979, 1975.PubMedCrossRefGoogle Scholar
  116. 116.
    Thung SN, Gerber MA, Klion F, et al: Massive hepatic necrosis after chemotherapy withdrawal in a hepatitis B virus carrier. Arch Intern Med 145: 1313–1314, 1985.PubMedCrossRefGoogle Scholar
  117. 117.
    Malone W, Novak R: Outcome of hepatitis in children with acute leukemia. Am J Dis Child 134: 584–587, 1980.PubMedGoogle Scholar
  118. 118.
    Locasciulli A, Alberti A, Barbieri R, et al: Evidence of non-A, non-R hepatitis in children with acute leukemia and chronic liver disease. Am J Dis Child 173: 354–356, 1983.Google Scholar
  119. 119.
    Barton JB, Conrad ME: Beneficial effects of hepatitis in patients with acute myelogenous leukemia. Ann Intern Med 90: 188–190, 1979.PubMedGoogle Scholar
  120. 120.
    Foon KA, Yale C, Clodfelter K, et al: Posttransfusion hepatitis in acute myelogenous leukemia: Effect on leukemia. JAMA 244: 1806–1807, 1980.PubMedCrossRefGoogle Scholar
  121. 121.
    Rotoli B, Formisano S, Martinelli V: Long-term survival in acute myelogenous leukemia complicated by chronic active hepatitis. (Letter.) N Engl J Med 307: 1712–1713, 1982.PubMedGoogle Scholar
  122. 122.
    Cacciola E, Giustolisi R: Acute myelogenous leukemia and hepatitis. (Letter.) Ann Intern Med 92: 127–128, 1980.PubMedGoogle Scholar
  123. 123.
    Brody SA, Russell WG, Krantz SB, et al: Beneficial effect of hepatitis in leukemic reticuloendotheliosis. Arch Intern Med 141: 1080–1081, 1981.PubMedCrossRefGoogle Scholar
  124. 124.
    Shepard KV, Levin B, Faintuch J, et al: Hepatitis as a beneficial prognostic factor in patients receiving intra-arterial chemotherapy for metastatic colorectal carcinoma. Clin Res 31:779A, 1983 (abst.).Google Scholar
  125. 125.
    Rosner F: Hepatitis and leukemia. (Letter.) Ann Intern Med 90: 853, 1979.PubMedGoogle Scholar
  126. 126.
    van den Ouweland FA, Holdrinet RSG, de Pauw BE, et al: Transaminase, hepatitis B, and prognosis in acute nonlymphoblastic leukemia. (Letter.) N Engl J Med 309: 990, 1983.PubMedGoogle Scholar
  127. 127.
    Julia A, Font L: Hepatitis and leukemia. (Letter.) Ann Intern Med 93: 780, 1980.PubMedGoogle Scholar
  128. 128.
    Carmichael GP, Zahradnik JM, Moyer GH, et al: Adenovirus hepatitis in an immunosuppressed adult patient. Am J Clin Pathol 71: 352–355, 1979.PubMedGoogle Scholar
  129. 129.
    Katz ME, Cassileth PA: Hyperbilirubinemia during induction therapy of acute granulocytic leukemia. Cancer 40: 1390–1392, 1977.CrossRefGoogle Scholar
  130. 130.
    Public Health Laboratory Service Survey: Hepatitis B in retreat from dialysis units in United Kingdom in 1973. Br Med J 1: 1579–1581, 1976.CrossRefGoogle Scholar
  131. 131.
    Postic B, Schreiner DP, Hanchett JE, et al: Containment of hepatitis B virus infection in a hemodialysis unit. J Infect Dis 138: 884–889, 1978.PubMedCrossRefGoogle Scholar
  132. 132.
    Najem GR, Louria DB, Thind IS, et al: Control of hepatitis B infection: The role of surveillance and an isolation hemodialysis center. JAMA 245: 153–157, 1981.PubMedCrossRefGoogle Scholar
  133. 133.
    Immunization Practices Advisory Committee: Recommendations for protection against viral hepatitis. MMWR 34: 313–324, 329–335, 1985.Google Scholar
  134. 134.
    Stevens CE, Szmuness W, Goodman AI, et al: Hepatitis B vaccine: Immune response in hemodialysis patients. Lancet 2: 1211–1213, 1980.PubMedCrossRefGoogle Scholar
  135. 135.
    Stevens CE, Alter HJ, Taylor PE, et al: Hepatitis B vaccine in patients receiving hemodialysis: Immunogenicity and efficacy. N Engl J Med 311: 496–501, 1984.PubMedCrossRefGoogle Scholar
  136. 136.
    Grob PI, Binswanger U, Zaruba K, et al: Immunogenicity of a hepatitis B subunit vaccine in hemodialysis and in renal transplant recipients. Antiviral Res 3: 43–52, 1983.PubMedCrossRefGoogle Scholar
  137. 137.
    Bergamini F, Zanetti AR, Ferroni P, et al: Immune response to hepatitis B vaccine in staff and patients in renal dialysis units. J Infect 7 (Suppl. 1): 35–40, 1983.PubMedCrossRefGoogle Scholar
  138. 138.
    Crosnier J, Jungers P, Courouce A-M, et al: Randomized placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units. II. Haemodialysis patients. Lancet 2: 797–800, 1981.CrossRefGoogle Scholar
  139. 139.
    Desmyter J, Colaert J, De Groot G, et al: Efficacy of heat-inactivated hepatitis B vaccine in hemodialysis patients and staff: Double-blind placebo-controlled trial. Lancet 2: 1323–1327, 1983.PubMedCrossRefGoogle Scholar
  140. 140.
    Desmyter J, Colaert J: Comparative immunogenicity of MSD, Pasteur and CLB hepatitis B vaccines in 245 hemodialysis patients (abst). In Vyas GN, Dienstag JL, Hoofnagle JH (eds): Viral Hepatitis and Liver Disease. Grune Strat ton, Orlando, 1984, pp. 709–710.Google Scholar
  141. 141.
    Jacobson IM, Jaffers G, Dienstag JL, et al: Immunogenicity of hepatitis B vaccine in renal transplant recipients. Trans plantation 39: 393–395, 1985.Google Scholar
  142. 142.
    Arnold W, Baumann W: Vaccination of children with malign nant diseases with alum-adsorbed hepatitis B vaccine—Im munogenicity studies. Scand J Infect Dis 38 (Suppl): 33–36, 1983.Google Scholar
  143. 143.
    Dienstag JL, Werner BF, Polk BF, et al: Hepatitis B vaccine in health care personnel: Safety, immunogenicity, and indi cators of efficacy. Ann Intern Med 101: 34–40, 1984.PubMedGoogle Scholar
  144. 144.
    Centers for Disease Control: Postexposure prophylaxis of hepatitis B: Recommendations of the Immunization Prac tices Advisory Committee. Ann Intern Med 101: 351–354, 1984.Google Scholar

Copyright information

© Springer Science+Business Media New York 1988

Authors and Affiliations

  • Jules L. Dienstag
    • 1
    • 2
  1. 1.Gastrointestinal Unit, Medical ServicesMassachusetts General HospitalBostonUSA
  2. 2.Department of MedicineHarvard Medical SchoolBostonUSA

Personalised recommendations